Science & Enterprise subscription

Follow us on Twitter

  • A new venture investment company is funding start-ups at their earliest stages, with a goal of increasing support f… https://t.co/mM44gsVcT9
    about 1 day ago
  • New post on Science and Enterprise: Early Venture Investors Aim for Diverse Entrepreneurs https://t.co/y9tdzGJ9rP #Science #Business
    about 1 day ago
  • Fascinating hypothesis. We wrote about this team's work in nanomedicine for crossing blood-brain barrier in October… https://t.co/ud8TGIrXt7
    about 1 day ago
  • The Food and Drug Administration issued its standards that developers need to meet in evidence submitted for review… https://t.co/0G93MkzRwL
    about 2 days ago
  • New post on Science and Enterprise: FDA Sets Review Criteria for Covid-19 Vaccines https://t.co/87eIr3uU3t #Science #Business
    about 2 days ago

Please share Science & Enterprise

In Case You Missed It …

(tigerlily713, Pixabay)

12 August 2018. Many of today’s cancer drugs are given with intravenous infusions to bypass digestive acids and enzymes that degrade and interfere with the active ingredients. We reported last week on a team at University of Colorado’s medical campus in Denver proposing a way to formulate cancer therapies as oral drugs. Their technique — use the components in milk that enable mothers to pass antibodies to their babies, shielded from the digestive system. NIH is funding the research with a 4-year award.

For this task, the researchers plan to harness exosomes, a topic we’ve written on a few times recently. Exosomes are tiny — 40 to 150 nanometer — lipid-membrane containers in cells that gather up and secrete cytoplasm, the gel-like material outside the cell nucleus. While originally believed to carry out waste removal and other maintenance tasks, exosomes are shown in recent years to perform useful delivery functions carrying proteins and genetic material to other cells, and drawing increased attention from a range of biological disciplines.

Here are other stories we covered last week:

*     *     *

Please share Science & Enterprise ...

Comments are closed.